Amylin Replacement Therapy in Patients With Type 1 Diabetes

Abstract

Amylin is a pancreatic β-cell hormone that is cosecreted with insulin and plays an important physiologic role in glucose homeostasis. Pramlintide is an analogue of amylin recently approved by the Food and Drug Administration and represents the first new treatment for people with type 1 diabetes since the discovery of insulin more than 80 years ago. Pramlintide has been shown to reduce the day-to-day fluctuations in glucose values that are commonly seen despite maximized insulin therapy alone. Additional proven clinical benefits include flattening of the postprandial glucose values, reducing the A1C, and concomitant weight loss. This combination of benefits makes pramlintide an important therapeutic tool for improving the metabolic control and quality of life of people with type 1 diabetes.

Get full access to this article

View all access options for this article.

References

Koro CE

Bowlin SJ

Bourgeois N

Fedder DO

. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27:17-20.

Jacobs MA

Keulen ET

Kanc K

et al.

Metabolic efficacy of preprandial administration of Lys(B28), Pro(B29) human insulin analog in IDDM patients: a comparison with human regular insulin during a three-meal test period. Diabetes Care. 1997;20: 1279-1286.

Purnell JQ

Hokanson JE

Marcovina SM

Steffes MW

Cleary PA

Brunzell JD

. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA. 1998;280:140-146.

United Kingdom Prospective Diabetes Study Group

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.

Koda JE

Fineman MS

Kolterman OG

Caro JF

. 24 hour plasma amylin profiles are elevated in IGT subjects vs. normal controls. Diabetes. 1995:44:238A.

Weyer C

Maggs DG

Young AA

Kolterman OG

. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des. 2001;14:1353-1373.

Fineman MS

Giotta MP

Thompson RG

Kolterman OG

Koda JE

. Amylin response following Sustacal® ingestion is diminished in type II diabetic patients treated with insulin. Diabetologia. 1996; 39:A149.

Kruger DF

Gatcomb PM

Owen SK

. Clinical implications of amylin and amylin deficiency. Diabetes Educ. 1999;25:389-397.

Young AA

Vine W

Gedulin BR

et al.

Preclinical pharmacology of pramlintide in the rat: comparisons with human and rat amylin. Drug Dev Res. 1966;37:231-248.

10.

Kolterman O

. Paper presented at: American Diabetes Association 63rd Scientific Sessions; June 13-17, 2003; New Orleans, La.

11.

Pramlintide [prescribing information]. San Diego, Calif: Amylin Pharmaceuticals, Inc; 2005.

12.

Weyer C

Gottlieb A

Kim DD

et al.

Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. Diabetes Care. 2003;26:3074-3079.

13.

Presentation to FDA Advisory Committee, July 2001. San Diego, Calif: Amylin Pharmaceuticals, Inc; 2005.

14.

Gottlieb A

Velte M

Fineman M

et al.

Pramlintide as an adjunct to insulin therapy improved glycemic and weight control in people with type 1 diabetes during treatment for 52 weeks [abstract]. Diabetes. 2000;49:A109. Abstract 439-P.

15.

Guthrie R

. Paper presented at: American Diabetes Association 65th Scientific Sessions; June 10-14, 2005; San Diego, Calif.

16.

Levetan C

Want LL

Weyer C

et al.

Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care. 2003;26:1-8.